These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18751401)

  • 1. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
    Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Knecht R; Hambek M
    Anticancer Res; 2008; 28(4B):2239-43. PubMed ID: 18751401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
    Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Hambek M; Knecht R
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):387-93. PubMed ID: 18830627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
    Wagenblast J; Hambek M; Baghi M; Knecht R
    Anticancer Res; 2008; 28(2A):687-92. PubMed ID: 18507008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
    Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; May A; Knecht R; Hambek M
    Oncol Rep; 2008 Nov; 20(5):1207-11. PubMed ID: 18949423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Wagenblast J; Hambek M; Baghi M; Gstöttner W; Strebhardt K; Ackermann H; Knecht R
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):323-30. PubMed ID: 17701215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
    Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
    Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
    Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A; Zeng Q; Wang CY
    Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
    Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
    Lorch JH; Thomas TO; Schmoll HJ
    Cancer Res; 2007 Jan; 67(2):727-34. PubMed ID: 17234784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
    Freudlsperger C; Thies A; Pfüller U; Schumacher U
    Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
    Kondo N; Ishiguro Y; Kimura M; Sano D; Fujita K; Sakakibara A; Taguchi T; Toth G; Matsuda H; Tsukuda M
    Oncol Rep; 2008 Aug; 20(2):373-8. PubMed ID: 18636200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.